Faddaoui Adnen, Sheta Razan, Bachvarova Magdalena, Plante Marie, Gregoire Jean, Renaud Marie-Claude, Sebastianelli Alexandra, Gobeil Stephane, Morin Chantale, Ghani Karim, Bachvarov Dimcho
a Department of Molecular Medicine , Université Laval , Québec , Canada.
b Centre de Recherche du CHU de Québec , L'Hôtel-Dieu de Québec , Québec , Canada.
Cell Cycle. 2017 Apr 3;16(7):693-706. doi: 10.1080/15384101.2017.1295181. Epub 2017 Feb 22.
Previously, we have identified the Grainyhead transcription factor 2 gene (GRHL2) as notably hypomethylated in high-grade (HG) serous epithelial ovarian tumors, compared with normal ovarian tissues. GRHL2 is known for its functions in normal tissue development and wound healing. In the context of cancer, the role of GRHL2 is still ambiguous as both tumorigenic and tumor suppressive functions have been reported for this gene, although a role of GRHL2 in maintaining the epithelial status of cancer cells has been suggested. In this study, we report that GRHL2 is strongly overexpressed in both low malignant potential (LMP) and HG serous epithelial ovarian tumors, which probably correlates with its hypomethylated status. Suppression of the GRHL2 expression led to a sharp decrease in cell proliferation, migration and invasion and induced G1 cell cycle arrest in epithelial ovarian cancer (EOC) cells displaying either epithelial (A2780s) or mesenchymal (SKOV3) phenotypes. However, no phenotypic alterations were observed in these EOC cell lines following GRHL2 silencing. Gene expression profiling and consecutive canonical pathway and network analyses confirmed these data, as in both these EOC cell lines, GRHL2 ablation was associated with the downregulation of various genes and pathways implicated in cell growth and proliferation, cell cycle control and cellular metabolism. Taken together, our data are indicative for a strong oncogenic potential of the GRHL2 gene in EOC progression and support recent findings on the role of GRHL2 as one of the major phenotypic stability factors (PSFs) that stabilize the highly aggressive/metastatic hybrid epithelial/mesenchymal (E/M) phenotype of cancer cells.
此前,我们已确定颗粒头转录因子2基因(GRHL2)在高级别(HG)浆液性上皮性卵巢肿瘤中显著低甲基化,与正常卵巢组织相比。GRHL2因其在正常组织发育和伤口愈合中的功能而闻名。在癌症背景下,GRHL2的作用仍不明确,尽管有研究表明GRHL2在维持癌细胞上皮状态方面发挥作用,但该基因的致癌和抑癌功能均有报道。在本研究中,我们报告GRHL2在低恶性潜能(LMP)和HG浆液性上皮性卵巢肿瘤中均强烈过表达,这可能与其低甲基化状态相关。抑制GRHL2表达导致细胞增殖、迁移和侵袭急剧下降,并在表现出上皮(A2780s)或间充质(SKOV3)表型的上皮性卵巢癌(EOC)细胞中诱导G1期细胞周期停滞。然而,GRHL2沉默后,这些EOC细胞系未观察到表型改变。基因表达谱分析以及随后的经典通路和网络分析证实了这些数据,因为在这两种EOC细胞系中,GRHL2缺失均与参与细胞生长和增殖、细胞周期控制及细胞代谢的各种基因和通路的下调有关。综上所述,我们的数据表明GRHL2基因在EOC进展中具有强大的致癌潜能,并支持了最近关于GRHL2作为稳定癌细胞高侵袭性/转移性混合上皮/间充质(E/M)表型的主要表型稳定性因子(PSF)之一的作用的研究结果。